Basilea Pharmaceutica AG Share Price
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
09:00:36 02/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 66.80 CHF | -1.47% |
|
-2.77% | +22.12% |
| 14/09 | Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains | MT |
| 14/09 | Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan | MT |
| Market Cap | 83Cr 100.03Cr 89Cr 76Cr 142.6Cr 9.62TCr 143.93Cr 1TCr 389.01Cr 4.92TCr 375.57Cr 367.42Cr 16TCr | P/E 2026 * |
15.5x | P/E 2027 * | 17.3x |
|---|---|---|---|---|---|
| Enterprise Value | 68Cr 82Cr 73Cr 62Cr 116.35Cr 7.85TCr 117.43Cr 819.1Cr 317.4Cr 4.01TCr 306.44Cr 299.79Cr 13TCr | EV / Sales 2026 * |
2.53x | EV / Sales 2027 * | 2.22x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
London S.E.
| 0QNA | Delayed | |
|
CBOE
| 0QNA | Real-time | |
|
Tradegate
| PK5 | Real-time | |
|
OTC Markets
| BPMUF | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -1.47% | ||
| 1 week | -2.77% | ||
| Current month | -4.43% | ||
| 1 month | +1.67% | ||
| 3 months | +25.80% | ||
| 6 months | +21.23% | ||
| Current year | +22.12% |
| 1 week | 66.3 |  | 70.1 |
| 1 month | 62.2 | | 70.5 |
| Current year | 47.8 | | 70.5 |
| 1 year | 44.7 | | 70.5 |
| 3 years | 32 | | 70.5 |
| 5 years | 29.55 | | 70.5 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/05/26 | Sell | -400 | 0.0030% | |||
| 13/05/26 | Sell | -1,043 | 0.0078% | |||
| 04/05/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.47% | -2.77% | +38.59% | +58.67% | 100.03Cr | |
| +4.16% | +3.04% | +49.37% | +94.17% | 7.42TCr | |
| -3.11% | -3.53% | +21.92% | +74.60% | 5.74TCr | |
| +0.89% | -0.63% | +4.28% | +34.51% | 4.76TCr | |
| +0.36% | +0.81% | +352.17% | +689.61% | 4.43TCr | |
| -0.96% | -4.50% | +26.36% | +33.18% | 4.25TCr | |
| -0.20% | -0.77% | +3.74% | +100.60% | 4.07TCr | |
| -0.54% | +2.93% | +9.31% | +50.41% | 3.1TCr | |
| -2.68% | +2.92% | +29.63% | +19.50% | 2.85TCr | |
| +0.05% | -1.64% | -7.28% | -14.06% | 2.43TCr | |
| Average | -0.35% | -0.81% | +52.81% | +114.12% | 3.92TCr | |
| Weighted average by Cap. | +0.12% | -0.84% | +58.71% | +129.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27Cr 32Cr 29Cr 24Cr 46Cr 3.11TCr 46Cr 324.25Cr 125.65Cr 1.59TCr 121.31Cr 118.67Cr 5.1TCr | 28Cr 33Cr 29Cr 25Cr 47Cr 3.19TCr 48Cr 333.01Cr 129.04Cr 1.63TCr 124.58Cr 121.88Cr 5.23TCr |
| Net income | 6.87Cr 8.28Cr 7.36Cr 6.26Cr 12Cr 796.37Cr 12Cr 83Cr 32Cr 407.11Cr 31Cr 30Cr 1.31TCr | 5.83Cr 7.03Cr 6.25Cr 5.31Cr 10Cr 675.85Cr 10Cr 71Cr 27Cr 345.5Cr 26Cr 26Cr 1.11TCr |
| Net Debt | -15Cr -18Cr -16Cr -14Cr -26Cr -1.77TCr -26Cr -184.79Cr -72Cr -904.92Cr -69Cr -68Cr -2.9TCr | -22Cr -26Cr -23Cr -20Cr -37Cr -2.53TCr -38Cr -263.69Cr -102.18Cr -1.29TCr -99Cr -97Cr -4.14TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | CHF 66.80 | -1.47% | 17,311 |
| 01/26/01 | CHF 67.80 | -3.00% | 24,214 |
| 30/26/30 | CHF 69.90 | +4.33% | 45,860 |
| 29/26/29 | CHF 67.00 | -1.90% | 20,986 |
| 28/26/28 | CHF 68.30 | -0.58% | 15,529 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
